[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100437810":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":280,"collaborators":282,"id":285,"slug":286,"hasResults":287,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":287,"sex":293,"minAge":294,"maxAge":7,"enrollmentInfo":295,"targetDuration":7,"studyType":298,"phases":7,"briefSummary":299,"conditions":300,"keywords":318,"overallStatus":33,"whyStopped":7,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":332},{"fullName":5,"class":6},"A2 Biotherapeutics Inc.","INDUSTRY",null,[9,13,17],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"OTHER","Apheresis","Apheresis procedure performed for collection of PBMCs.",{"type":14,"name":15,"description":16,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Next Generation Sequencing (NGS)","NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.",{"type":14,"name":18,"description":19,"armGroupLabels":7,"otherNames":7},"Long Range NGS HLA typing","Long range NGS on whole blood to determine germline HLA type.",[21],{"name":22,"affiliation":5,"role":23},"Eric W Ng, MD, FAAP","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":7,"email":29},"Clinical Trials","CONTACT","(310)431-9180","ClinicalTrials@a2bio.com",[31,53,68,79,94,109,127,143,160,170,188,204,219,236,253,263],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Banner Health","RECRUITING","Gilbert","Arizona","85234","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-111.78903,33.35283,{"lat":43,"lon":42},[46,50],{"name":47,"role":27,"phone":48,"phoneExt":7,"email":49},"Jace Luzania","480-256-5483","Jace.Luzania@bannerhealth.com",{"name":51,"role":52,"phone":7,"phoneExt":7,"email":7},"Matthew Ulrickson, MD","PRINCIPAL_INVESTIGATOR",{"facility":54,"status":33,"city":55,"state":35,"zip":56,"country":37,"countryCode":38,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Mayo Clinic Hospital","Phoenix","85054",{"type":40,"coordinates":58},[59,60],-112.07404,33.44838,{"lat":60,"lon":59},[63,66],{"name":64,"role":27,"phone":65,"phoneExt":7,"email":7},"Clinical Trials Referral Office","855-776-0015",{"name":67,"role":52,"phone":7,"phoneExt":7,"email":7},"Antonious Hazim, MD",{"facility":69,"status":70,"city":71,"state":72,"zip":73,"country":37,"countryCode":38,"cosmosGeoPoint":74,"geoPoint":78,"contacts":7},"City of Hope","COMPLETED","Duarte","California","90101",{"type":40,"coordinates":75},[76,77],-117.97729,34.13945,{"lat":77,"lon":76},{"facility":80,"status":33,"city":81,"state":72,"zip":82,"country":37,"countryCode":38,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"University of California San Diego","La Jolla","92093",{"type":40,"coordinates":84},[85,86],-117.2742,32.84727,{"lat":86,"lon":85},[89,92],{"name":90,"role":27,"phone":7,"phoneExt":7,"email":91},"Anthony Oshmago","aoshmago@health.ucsd.edu",{"name":93,"role":52,"phone":7,"phoneExt":7,"email":7},"Sandip Patel, MD",{"facility":95,"status":33,"city":96,"state":72,"zip":97,"country":37,"countryCode":38,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Stanford University","Palo Alto","94304",{"type":40,"coordinates":99},[100,101],-122.14302,37.44188,{"lat":101,"lon":100},[104,107],{"name":105,"role":27,"phone":7,"phoneExt":7,"email":106},"Vivian Leung","vivian0@stanford.edu",{"name":108,"role":52,"phone":7,"phoneExt":7,"email":7},"Wen-Kai Weng, MD",{"facility":110,"status":33,"city":111,"state":72,"zip":112,"country":37,"countryCode":38,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"UCLA Medical Center","Santa Monica","90404",{"type":40,"coordinates":114},[115,116],-118.49138,34.01949,{"lat":116,"lon":115},[119,122,124],{"name":120,"role":27,"phone":7,"phoneExt":7,"email":121},"Karla Largaespada","KLargaespada@mednet.ucla.edu",{"name":123,"role":52,"phone":7,"phoneExt":7,"email":7},"J. Randolph Hecht, MD",{"name":125,"role":126,"phone":7,"phoneExt":7,"email":7},"Edward Garon, MD","SUB_INVESTIGATOR",{"facility":128,"status":33,"city":129,"state":130,"zip":131,"country":37,"countryCode":38,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Mayo Clinic Jacksonville","Jacksonville","Florida","32224",{"type":40,"coordinates":133},[134,135],-81.65565,30.33218,{"lat":135,"lon":134},[138,141],{"name":139,"role":27,"phone":7,"phoneExt":7,"email":140},"Rhoda Romain","Romain.Rhoda@mayo.edu",{"name":142,"role":52,"phone":7,"phoneExt":7,"email":7},"Yanyan Lou, MD, PhD",{"facility":144,"status":33,"city":145,"state":130,"zip":146,"country":37,"countryCode":38,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Moffitt Cancer Center","Tampa","33136",{"type":40,"coordinates":148},[149,150],-82.45843,27.94752,{"lat":150,"lon":149},[153,156,158],{"name":154,"role":27,"phone":7,"phoneExt":7,"email":155},"Katie Ehm","Katie.Ehm@moffitt.org",{"name":157,"role":52,"phone":7,"phoneExt":7,"email":7},"Kedar Kirtane, MD",{"name":159,"role":126,"phone":7,"phoneExt":7,"email":7},"Frederick Locke, MD",{"facility":161,"status":70,"city":162,"state":163,"zip":164,"country":37,"countryCode":38,"cosmosGeoPoint":165,"geoPoint":169,"contacts":7},"Massachusetts General Hospital\u002FDana Farber Cancer Institute","Boston","Massachusetts","02114",{"type":40,"coordinates":166},[167,168],-71.05977,42.35843,{"lat":168,"lon":167},{"facility":171,"status":33,"city":172,"state":173,"zip":174,"country":37,"countryCode":38,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Mayo Clinic Rochester","Rochester","Minnesota","55905",{"type":40,"coordinates":176},[177,178],-92.4699,44.02163,{"lat":178,"lon":177},[181,184,186],{"name":182,"role":27,"phone":7,"phoneExt":7,"email":183},"Ethan Sunsvold","Sundsvold.Ethan@mayo.edu",{"name":185,"role":52,"phone":7,"phoneExt":7,"email":7},"Julian Molina, MD, PhD",{"name":187,"role":126,"phone":7,"phoneExt":7,"email":7},"Yi Lin, MD, PhD",{"facility":189,"status":33,"city":190,"state":191,"zip":192,"country":37,"countryCode":38,"cosmosGeoPoint":193,"geoPoint":197,"contacts":198},"Washington University","St Louis","Missouri","63110",{"type":40,"coordinates":194},[195,196],-90.19789,38.62727,{"lat":196,"lon":195},[199,202],{"name":200,"role":27,"phone":7,"phoneExt":7,"email":201},"Hussain Hassan","hahassan@wustl.edu",{"name":203,"role":52,"phone":7,"phoneExt":7,"email":7},"Patrick Grierson, MD, PhD",{"facility":205,"status":33,"city":206,"state":206,"zip":207,"country":37,"countryCode":38,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"NYU Langone Medical Center","New York","10016",{"type":40,"coordinates":209},[210,211],-74.00597,40.71427,{"lat":211,"lon":210},[214,217],{"name":215,"role":27,"phone":7,"phoneExt":7,"email":216},"Kennedi Rainey","Kennedi.Rainey@nyulangone.org",{"name":218,"role":52,"phone":7,"phoneExt":7,"email":7},"Kristen Spencer, DO",{"facility":220,"status":33,"city":221,"state":222,"zip":223,"country":37,"countryCode":38,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"The Ohio State University Comprehensive Cancer Center","Columbus","Ohio","43210",{"type":40,"coordinates":225},[226,227],-82.99879,39.96118,{"lat":227,"lon":226},[230,234],{"name":231,"role":27,"phone":232,"phoneExt":7,"email":233},"Dudbeth Brown","614-685-7034","Dudbeth.Brown@osumc.edu",{"name":235,"role":52,"phone":7,"phoneExt":7,"email":7},"Jinesh Gheeya, MD, PhD",{"facility":237,"status":33,"city":238,"state":239,"zip":240,"country":37,"countryCode":38,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"Vanderbilt University Medical Center","Nashville","Tennessee","37232",{"type":40,"coordinates":242},[243,244],-86.78444,36.16589,{"lat":244,"lon":243},[247,251],{"name":248,"role":27,"phone":249,"phoneExt":7,"email":250},"Vanderbilt-Ingram Cancer Center Clinical Trials Office (CTO)","1-800-811-8480","CTIP@VUMC.ORG",{"name":252,"role":52,"phone":7,"phoneExt":7,"email":7},"Cathy Eng, M.D., FACP, FASCO",{"facility":254,"status":70,"city":255,"state":256,"zip":257,"country":37,"countryCode":38,"cosmosGeoPoint":258,"geoPoint":262,"contacts":7},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":40,"coordinates":259},[260,261],-95.36327,29.76328,{"lat":261,"lon":260},{"facility":264,"status":33,"city":265,"state":266,"zip":267,"country":37,"countryCode":38,"cosmosGeoPoint":268,"geoPoint":272,"contacts":273},"Fred Hutchinson Cancer Center","Seattle","Washington","98109",{"type":40,"coordinates":269},[270,271],-122.33207,47.60621,{"lat":271,"lon":270},[274,276,278],{"name":275,"role":27,"phone":7,"phoneExt":7,"email":7},"Shelby Colden",{"name":7,"role":27,"phone":7,"phoneExt":7,"email":277},"scolden2@fredhutch.org",{"name":279,"role":52,"phone":7,"phoneExt":7,"email":7},"Jennifer Specht, MD",{"type":281,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[283],{"name":284,"class":6},"Tempus AI","100437810","solid-tumor-analysis-for-hla-loss-of-heterozygosity-loh-and-apheresis-for-car-t--cell-manufacturing-100437810",false,"NCT04981119","Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing","An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing","BASECAMP-1","Key Eligibility Criteria (additional criteria may apply) Part 1 Key Inclusion Criteria\n\n1\\. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), or Pancreatic Cancer (PANC), that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n\nPart 1: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n\nPart 2 : Key Inclusion Criteria\n\n1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PANC), Mesothelioma, or Ovarian Cancer (OVAC) that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n2. Participants are germline HLA-A\\*02 heterozygous confirmed by HLA typing.\n3. Primary tumor tissue showing LOH of HLA-A\\*02 by NGS testing.\n4. Eastern Cooperative Oncology Group (ECOG) 0 or 1 performance status.\n\nPart 2: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n4. Participants who have received any cancer therapy on any investigational therapy for any indication, including but not limited to chemotherapy, small molecules, monoclonal antibodies, or radiotherapy (with bone marrow impact) within 2 weeks of planned apheresis or 3 half-lives, whichever is shorter.\n5. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment necessitating specific treatment, or any major episode of infection requiring treatment with Intravenous (IV) antimicrobials (e.g., IV antibiotics) or hospitalization (relating to completion of antibiotic course).\n6. Has known active central nervous system metastases. Subjects with previously treated brain metastases may participate upon medical monitor agreement.\n7. In the Investigator's judgement, any other condition or reason the subject would not complete the required study visits and procedures, and follow up visits, or comply with the study requirements for participation.","ALL","18 Years",{"count":296,"type":297},200,"ESTIMATED","OBSERVATIONAL","Objective:\n\nTo collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment.\n\nDesign:\n\nThis is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.",[301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317],"Solid Tumor, Adult","Colorectal Cancer","Non Small Cell Lung Cancer","Pancreatic Cancer","CRC","NSCLC","Pancreas Cancer","Mesothelioma","Ovarian Cancer","Ovarian Neoplasms","Ovarian Carcinoma","Mesothelioma, Malignant","Mesothelioma; Lung","Cancer","Triple Negative Breast Cancer (TNBC)","Renal Cell Carcinoma (Kidney Cancer)","Head and Neck Squamous Cell Carcinoma HNSCC",[319,320,321,11,322],"CAR T Cell Therapy","Next Generation Sequencing","Leukapheresis","Immunotherapy","2026-05-29",{"date":325,"type":326},"2026-06-02","ACTUAL",{"date":328,"type":326},"2021-10-29",{"date":330,"type":297},"2029-04",{"name":5,"class":6},16]